SynthesisAnnals of oncology : official journal of the European Society for Medical Oncology2012

Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.

T Reiman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.